These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 28798071)

  • 1. Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm.
    Philippe L; Ceroi A; Bôle-Richard E; Jenvrin A; Biichle S; Perrin S; Limat S; Bonnefoy F; Deconinck E; Saas P; Garnache-Ottou F; Angelot-Delettre F
    Haematologica; 2017 Nov; 102(11):1861-1868. PubMed ID: 28798071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.
    Angelot-Delettre F; Roggy A; Frankel AE; Lamarthee B; Seilles E; Biichle S; Royer B; Deconinck E; Rowinsky EK; Brooks C; Bardet V; Benet B; Bennani H; Benseddik Z; Debliquis A; Lusina D; Roussel M; Solly F; Ticchioni M; Saas P; Garnache-Ottou F
    Haematologica; 2015 Feb; 100(2):223-30. PubMed ID: 25381130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rare case of blastic plasmacytoid dendritic cell neoplasm with deletion 7q.31, in the setting of heavy pre-treatment with alkylating chemotherapy.
    Kaur V; Swami A; Shebli A; Shalin S; Veeraputhiran M; Emanuel P; Jethava Y
    J Oncol Pharm Pract; 2017 Oct; 23(7):552-556. PubMed ID: 27559020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis.
    Ceroi A; Masson D; Roggy A; Roumier C; Chagué C; Gauthier T; Philippe L; Lamarthée B; Angelot-Delettre F; Bonnefoy F; Perruche S; Biichle S; Preudhomme C; Macintyre E; Lagrost L; Garnache-Ottou F; Saas P
    Blood; 2016 Dec; 128(23):2694-2707. PubMed ID: 27702801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib, Lenalidomide, and Dexamethasone in Elderly Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Chahine C; Roos-Weil D; Saada V; de Botton S; Micol JB; Barete S; Marzac C; Ghez D
    Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):e986-e989. PubMed ID: 32917576
    [No Abstract]   [Full Text] [Related]  

  • 6. Blastic Plasmacytoid Dendritic Cell Neoplasm: From Origin of the Cell to Targeted Therapies.
    Laribi K; Denizon N; Besançon A; Farhi J; Lemaire P; Sandrini J; Truong C; Ghnaya H; Baugier de Materre A
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1357-1367. PubMed ID: 27026248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An unusual case of cutaneous blastic plasmacytoid dendritic cell neoplasm with concomitant B-cell lymphoproliferative disorder.
    Patel JL; Shetty S; Salama ME
    Am J Dermatopathol; 2011 May; 33(3):e31-6. PubMed ID: 20861710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.
    Montero J; Stephansky J; Cai T; Griffin GK; Cabal-Hierro L; Togami K; Hogdal LJ; Galinsky I; Morgan EA; Aster JC; Davids MS; LeBoeuf NR; Stone RM; Konopleva M; Pemmaraju N; Letai A; Lane AA
    Cancer Discov; 2017 Feb; 7(2):156-164. PubMed ID: 27986708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition.
    Sapienza MR; Fuligni F; Agostinelli C; Tripodo C; Righi S; Laginestra MA; Pileri A; Mancini M; Rossi M; Ricci F; Gazzola A; Melle F; Mannu C; Ulbar F; Arpinati M; Paulli M; Maeda T; Gibellini D; Pagano L; Pimpinelli N; Santucci M; Cerroni L; Croce CM; Facchetti F; Piccaluga PP; Pileri SA;
    Leukemia; 2014 Aug; 28(8):1606-16. PubMed ID: 24504027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway.
    Yang L; Chen J; Han X; Zhang E; Huang X; Guo X; Chen Q; Wu W; Zheng G; He D; Zhao Y; Yang Y; He J; Cai Z
    Protein Cell; 2018 Sep; 9(9):770-784. PubMed ID: 29441489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous accumulation of plasmacytoid dendritic cells associated with acute myeloid leukemia: a rare condition distinct from blastic plasmacytoid dendritic cell neoplasm.
    Dargent JL; Delannoy A; Pieron P; Husson B; Debecker C; Petrella T
    J Cutan Pathol; 2011 Nov; 38(11):893-8. PubMed ID: 21883371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blastic plasmacytoid dendritic cell neoplasm: a clinicopathologic review.
    Shi Y; Wang E
    Arch Pathol Lab Med; 2014 Apr; 138(4):564-9. PubMed ID: 24678689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells.
    Tamatani T; Takamaru N; Hara K; Kinouchi M; Kuribayashi N; Ohe G; Uchida D; Fujisawa K; Nagai H; Miyamoto Y
    Int J Oncol; 2013 Mar; 42(3):935-44. PubMed ID: 23340716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel agents.
    Wang S; Wang X; Liu M; Bai O
    Ann Hematol; 2018 Apr; 97(4):563-572. PubMed ID: 29455234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effect of lenalidomide in a novel xenograft mouse model of human blastic NK cell lymphoma/blastic plasmacytoid dendritic cell neoplasm.
    Agliano A; Martin-Padura I; Marighetti P; Gregato G; Calleri A; Prior C; Redrado M; Calvo A; Bertolini F
    Clin Cancer Res; 2011 Oct; 17(19):6163-73. PubMed ID: 21856771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.
    Sunwoo JB; Chen Z; Dong G; Yeh N; Crowl Bancroft C; Sausville E; Adams J; Elliott P; Van Waes C
    Clin Cancer Res; 2001 May; 7(5):1419-28. PubMed ID: 11350913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skin lesions in a patient with blastic plasmacytoid dendritic cell neoplasm.
    Dlouhy I; Santacruz R; Peña O
    Br J Haematol; 2014 Mar; 164(6):758. PubMed ID: 24372537
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical efficacy of bortezomib and lenalidomide in blastic plasmacytoid dendritic cell neoplasm.
    Yang C; Fu C; Feng Y; Zhao S; Weng H; Zhang L; Du H; Zou L
    Ann Hematol; 2019 Jun; 98(6):1525-1527. PubMed ID: 30694364
    [No Abstract]   [Full Text] [Related]  

  • 19. [Blastic plasmacytoid dendritic cell neoplasm: a clinicopathologic study].
    Sang W; Wang CF; Cheng YF; Liu X; Li XX; Gulinar A; Li JZ; Zhang W
    Zhonghua Bing Li Xue Za Zhi; 2012 May; 41(5):326-30. PubMed ID: 22883672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond.
    Pemmaraju N
    Curr Hematol Malig Rep; 2017 Dec; 12(6):510-512. PubMed ID: 29064022
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.